# Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

> **NCT01614457** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 70 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Ivacaftor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01614457
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01614457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01614457, "Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01614457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*